File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prednisolone in HBsAg-positive chronic active hepatitis: Histologic evaluation in a controlled prospective study

TitlePrednisolone in HBsAg-positive chronic active hepatitis: Histologic evaluation in a controlled prospective study
Authors
Issue Date1982
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 1982, v. 2 n. 6, p. 777-783 How to Cite?
AbstractTo study the value of corticosterone in HBsAg-positive chronic active hepatitis, 18 pairs of liver histology comprising 36 liver biopsies from a prospective, randomized, controlled trial were evaluated. The median interval between the initial and follow-up histology was 8 1/2 months in 8 patients given prednisolone and 8 1/4 months in 10 patients given placebo tablets. Following medication, there was significantly greater erosion of the limiting plate in the prenisolone group (p = 0.039) accompanied by a larger quantity HBsAg (p = 0.045) and HBcAg (p = 0.006) in the liver. We conclude that prednisolone causes immunosuppression permitting enhanced viral multiplication and leads to increased erosion of the limiting plate. Our result also indicates that progression to cirrhosis is unhalted by prednisolone therapy. The histologic findings support clinico-biochemical conclusion that the use of prednisolone is deleterious to patients with HBsAg-positive chronic active hepatitis.
Persistent Identifierhttp://hdl.handle.net/10722/161668
ISSN
2023 Impact Factor: 12.9
2023 SCImago Journal Rankings: 5.011
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWu, PCen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorLam, KCen_US
dc.contributor.authorHo, Jen_US
dc.date.accessioned2012-09-05T05:13:42Z-
dc.date.available2012-09-05T05:13:42Z-
dc.date.issued1982en_US
dc.identifier.citationHepatology, 1982, v. 2 n. 6, p. 777-783en_US
dc.identifier.issn0270-9139en_US
dc.identifier.urihttp://hdl.handle.net/10722/161668-
dc.description.abstractTo study the value of corticosterone in HBsAg-positive chronic active hepatitis, 18 pairs of liver histology comprising 36 liver biopsies from a prospective, randomized, controlled trial were evaluated. The median interval between the initial and follow-up histology was 8 1/2 months in 8 patients given prednisolone and 8 1/4 months in 10 patients given placebo tablets. Following medication, there was significantly greater erosion of the limiting plate in the prenisolone group (p = 0.039) accompanied by a larger quantity HBsAg (p = 0.045) and HBcAg (p = 0.006) in the liver. We conclude that prednisolone causes immunosuppression permitting enhanced viral multiplication and leads to increased erosion of the limiting plate. Our result also indicates that progression to cirrhosis is unhalted by prednisolone therapy. The histologic findings support clinico-biochemical conclusion that the use of prednisolone is deleterious to patients with HBsAg-positive chronic active hepatitis.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_US
dc.relation.ispartofHepatologyen_US
dc.subject.meshBiopsyen_US
dc.subject.meshHepatitis B Core Antigens - Analysisen_US
dc.subject.meshHepatitis B Surface Antigensen_US
dc.subject.meshHepatitis, Chronic - Drug Therapy - Pathologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver - Pathologyen_US
dc.subject.meshLiver Regenerationen_US
dc.subject.meshPrednisolone - Adverse Effectsen_US
dc.subject.meshProspective Studiesen_US
dc.titlePrednisolone in HBsAg-positive chronic active hepatitis: Histologic evaluation in a controlled prospective studyen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hep.1840020605-
dc.identifier.pmid7141388-
dc.identifier.scopuseid_2-s2.0-0020373510en_US
dc.identifier.volume2en_US
dc.identifier.issue6en_US
dc.identifier.spage777en_US
dc.identifier.epage783en_US
dc.identifier.isiWOS:A1982PS02600004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridLam, KC=7403657286en_US
dc.identifier.scopusauthoridHo, J=7402649982en_US
dc.identifier.issnl0270-9139-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats